Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab beyond progression in metastatic colorectal cancer
NCT01077739Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2009
- Primary completion
- Jan 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in colorectal cancer (CRC), sponsored by Roche. Primary endpoint: Progression-Free Survival From the Start of Treatment Beyond Progression up to 24 months. Started Jul 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01077739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01077739.